This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology; Alzheimer's disease	Microtubule- associated protein- τ (MAPT; TAU; FTDP-17)	<i>In vitro</i> and animal studies suggest that blocking acetylation of TAU at lysine 280 could help treat neurological disorders associated with TAU. <i>In vitro</i> , TAU acetylation at lysine 280 was associated with impaired TAU function. In mouse tauopathy models and samples from patients with various tauopathy disorders, acetylation at lysine 280 was associated with disease pathology. Next steps include identifying the acetyltransferase and deacetylase enzymes that mediate TAU acetylation at lysine 280.	Patent application filed covering TAU acetylation at lysine 280 as a biomarker for tauopathies; unavailable for licensing	Cohen, T.J. <i>et al. Nat. Commun.</i> ; published online March 22, 2011; doi:10.1038/ncomms1255 Contact: Virginia M.Y. Lee, University of Pennsylvania, Philadelphia, Pa. e-mail: vmylee@upenn.edu
SciBX 4(13); doi:10.1038/scibx.2011.378 Published online March 31, 2011				